


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app39.us.archive.org';v.server_ms=472;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Systemic therapy for unresectable stage III or metastatic cutaneous melanoma. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180713024956im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180713024956im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180713024956im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180713024956im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180713024956/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180713024956im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180713024956cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180713024956js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180713024956if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713024956/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180713024956if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713024956/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180713024956/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180713024956/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180713024956/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180713024956/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180713024956/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180713024956/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180713024956/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180713024956/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180713024956/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180713024956/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180713024956/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180713024956/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180713024956/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180713024956/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180713024956/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180713024956/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180713024956/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180713024956/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180713024956/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180713024956/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180713024956/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180713024956/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180713024956/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180713024956/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010882</li>
            <li>2015 Aug
            </li>            
                                </ul>
        <div>
                <h1>Systemic therapy for unresectable stage III or metastatic cutaneous melanoma.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180713024956/https://www.guideline.gov/search?f_Guideline_Developer_String=CancerControl%20Alberta&amp;fLockTerm=CancerControl%2BAlberta">CancerControl Alberta</a></li>
                        <li>   
                                <a id="2278" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Alberta Provincial Cutaneous Tumour Team. Systemic therapy for unresectable stage III or metastatic cutaneous melanoma. Edmonton (AB): CancerControl Alberta; 2015 Aug. 14 p.&nbsp;(Clinical practice guideline; no. CU-012).&nbsp; [43 references]</td></tr></table>                    <p><a href="/web/20180713024956/https://www.guideline.gov/Home/Disclaimer?id=49966&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fwww.albertahealthservices.ca%252fassets%252finfo%252fhp%252fcancer%252fif-hp-cancer-guide-cu012-systemic-therapy.pdf">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713024956im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Alberta Provincial Cutaneous Tumour Team. Systemic therapy for unresectable stage III or metastatic cutaneous melanoma. Edmonton (Alberta): CancerControl Alberta; 2013 Feb. 13 p. (Clinical practice guideline; no. CU-012). [59 references]</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180713024956/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
                        <li><a href="/web/20180713024956/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&amp;fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>                      
                        <li><a href="/web/20180713024956/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&amp;fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>                      
                        <li><a href="/web/20180713024956/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180713024956/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180713024956/https://www.guideline.gov/search?f_ICD9CM_CUI=C0153537&amp;fLockTerm=Malignant+melanoma+of+other+specified+sites+of+skin">Malignant melanoma of other specified sites of skin</a>
 (172.8), <a href="/web/20180713024956/https://www.guideline.gov/search?f_ICD9CM_CUI=C0151779&amp;fLockTerm=Melanoma+of+skin%2c+site+unspecified">Melanoma of skin, site unspecified</a>
 (172.9)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0003250&amp;fLockTerm=Antibodies%2c+Monoclonal">Antibodies, Monoclonal</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C2985546&amp;fLockTerm=Antibodies%2c+Monoclonal%2c+Humanized">Antibodies, Monoclonal, Humanized</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0003392&amp;fLockTerm=Antineoplastic+Agents">Antineoplastic Agents</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0004490&amp;fLockTerm=Azetidines">Azetidines</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0041366&amp;fLockTerm=Biomarkers%2c+Tumor">Biomarkers, Tumor</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0085533&amp;fLockTerm=Chemotherapy%2c+Adjuvant">Chemotherapy, Adjuvant</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0008976&amp;fLockTerm=Clinical+Trials+as+Topic">Clinical Trials as Topic</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0010927&amp;fLockTerm=Dacarbazine">Dacarbazine</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0679560&amp;fLockTerm=Genetic+Testing">Genetic Testing</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0020924&amp;fLockTerm=Imidazoles">Imidazoles</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0021242&amp;fLockTerm=Indoles">Indoles</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C1367202&amp;fLockTerm=Ipilimumab">Ipilimumab</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0025202&amp;fLockTerm=Melanoma">Melanoma</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C2699893&amp;fLockTerm=Molecular+Targeted+Therapy">Molecular Targeted Therapy</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0027627&amp;fLockTerm=Neoplasm+Metastasis">Neoplasm Metastasis</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0030020&amp;fLockTerm=Oximes">Oximes</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0031960&amp;fLockTerm=Piperidines">Piperidines</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C1449702&amp;fLockTerm=Protein+Kinase+Inhibitors">Protein Kinase Inhibitors</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0104940&amp;fLockTerm=Proto-Oncogene+Proteins+B-raf">Proto-Oncogene Proteins B-raf</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0034260&amp;fLockTerm=Pyridones">Pyridones</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0034290&amp;fLockTerm=Pyrimidinones">Pyrimidinones</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0037286&amp;fLockTerm=Skin+Neoplasms">Skin Neoplasms</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MSH_CUI=C0038760&amp;fLockTerm=Sulfonamides">Sulfonamides</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0003392&amp;fLockTerm=Antineoplastic+Agents">Antineoplastic Agents</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0004490&amp;fLockTerm=Azetidines">Azetidines</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C3251771&amp;fLockTerm=braf+gene+analysis">braf gene analysis</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C1259929&amp;fLockTerm=BRAF+protein%2c+human">BRAF protein, human</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0008976&amp;fLockTerm=Clinical+Trials">Clinical Trials</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0151779&amp;fLockTerm=Cutaneous+Melanoma">Cutaneous Melanoma</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C3467876&amp;fLockTerm=dabrafenib">dabrafenib</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0010927&amp;fLockTerm=Dacarbazine">Dacarbazine</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0679560&amp;fLockTerm=Genetic+screening+method">Genetic screening method</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0020924&amp;fLockTerm=Imidazoles">Imidazoles</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0021242&amp;fLockTerm=Indoles">Indoles</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C1367202&amp;fLockTerm=ipilimumab">ipilimumab</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0025202&amp;fLockTerm=melanoma">melanoma</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0003250&amp;fLockTerm=Monoclonal+Antibodies">Monoclonal Antibodies</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0027627&amp;fLockTerm=Neoplasm+Metastasis">Neoplasm Metastasis</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C1449702&amp;fLockTerm=Protein+Kinase+Inhibitors">Protein Kinase Inhibitors</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0034260&amp;fLockTerm=Pyridones">Pyridones</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0037286&amp;fLockTerm=Skin+Neoplasms">Skin Neoplasms</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0441771&amp;fLockTerm=Stage+level+3">Stage level 3</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C0038760&amp;fLockTerm=Sulfonamides">Sulfonamides</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_MTH_CUI=C3192263&amp;fLockTerm=Vemurafenib">Vemurafenib</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180713024956/https://www.guideline.gov/search?f_PDQ_CUI=C0010927&amp;fLockTerm=dacarbazine">dacarbazine</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_PDQ_CUI=C1367202&amp;fLockTerm=ipilimumab">ipilimumab</a>
, <a href="/web/20180713024956/https://www.guideline.gov/search?f_PDQ_CUI=C0037286&amp;fLockTerm=skin+tumor">skin tumor</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003392&amp;fLockTerm=Antineoplastic+agent">Antineoplastic agent</a>
 (27867009), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003392&amp;fLockTerm=Antineoplastic+agent">Antineoplastic agent</a>
 (372688009), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041366&amp;fLockTerm=Biochemical+tumor+marker">Biochemical tumor marker</a>
 (259672007), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0008976&amp;fLockTerm=Clinical+trial">Clinical trial</a>
 (110465008), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C3467876&amp;fLockTerm=Dabrafenib">Dabrafenib</a>
 (703641001), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C3467876&amp;fLockTerm=Dabrafenib">Dabrafenib</a>
 (703646006), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0010927&amp;fLockTerm=Dacarbazine">Dacarbazine</a>
 (387441003), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0010927&amp;fLockTerm=Dacarbazine">Dacarbazine</a>
 (77750008), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0679560&amp;fLockTerm=Genetic+test">Genetic test</a>
 (405824009), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1367202&amp;fLockTerm=Ipilimumab">Ipilimumab</a>
 (697995005), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1367202&amp;fLockTerm=Ipilimumab">Ipilimumab</a>
 (704649006), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025202&amp;fLockTerm=Malignant+melanoma">Malignant melanoma</a>
 (2092003), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0025202&amp;fLockTerm=Malignant+melanoma">Malignant melanoma</a>
 (372244006), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0151779&amp;fLockTerm=Malignant+melanoma+of+skin">Malignant melanoma of skin</a>
 (93655004), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0752096&amp;fLockTerm=Molecular+testing%2c+diagnostic">Molecular testing, diagnostic</a>
 (396927009), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003250&amp;fLockTerm=Monoclonal+antibody">Monoclonal antibody</a>
 (49616005), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0037286&amp;fLockTerm=Neoplasm+of+skin">Neoplasm of skin</a>
 (126488004), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0030020&amp;fLockTerm=Oxime">Oxime</a>
 (440250004), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1449702&amp;fLockTerm=Protein+kinase+inhibitor">Protein kinase inhibitor</a>
 (426265004), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1449702&amp;fLockTerm=Protein+kinase+inhibitor">Protein kinase inhibitor</a>
 (427510007), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0441771&amp;fLockTerm=Stage+level+3">Stage level 3</a>
 (258224005), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0441771&amp;fLockTerm=Stage+level+3">Stage level 3</a>
 (83606005), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0038760&amp;fLockTerm=Sulfonamide">Sulfonamide</a>
 (387406002), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C3192263&amp;fLockTerm=Vemurafenib">Vemurafenib</a>
 (702805007), <a href="/web/20180713024956/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C3192263&amp;fLockTerm=Vemurafenib">Vemurafenib</a>
 (703656005)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180713024956/https://www.guideline.gov/search?f_UMD_CUI=C1608350&amp;fLockTerm=Analyzers%2c+Laboratory%2c+Molecular+Assay%2c+Genetic+Testing">Analyzers, Laboratory, Molecular Assay, Genetic Testing</a>
 (20-803), <a href="/web/20180713024956/https://www.guideline.gov/search?f_UMD_CUI=C4052956&amp;fLockTerm=IVD+Test+Reagent%2fKits%2c+Molecular+Assay%2c+Gene+Anomaly%2c+Deletion%2fDuplication%2c+BRAF">IVD Test Reagent/Kits, Molecular Assay, Gene Anomaly, Deletion/Duplication, BRAF</a>
 (34-830), <a href="/web/20180713024956/https://www.guideline.gov/search?f_UMD_CUI=C4052955&amp;fLockTerm=IVD+Test+Reagent%2fKits%2c+Molecular+Assay%2c+Gene+Anomaly%2c+Mutation%2c+BRAF">IVD Test Reagent/Kits, Molecular Assay, Gene Anomaly, Mutation, BRAF</a>
 (34-829)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/downloadcontent/ngc-10882?contentType=pdf" class="pdf">.PDF 90.4 kb</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/downloadcontent/ngc-10882?contentType=word" class="word">Word Document 284.4 kb</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/downloadcontent/ngc-10882?contentType=xml" class="xml">.XML 33.9 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180713024956/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713024956/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713024956/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180713024956/mailto:/?Subject=AHRQ: Systemic therapy for unresectable stage III or metastatic cutaneous melanoma.&amp;body=https://www.guideline.gov/summaries/summary/49966/systemic-therapy-for-unresectable-stage-iii-or-metastatic-cutaneous-melanoma" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Systemic therapy for unresectable stage III or metastatic cutaneous melanoma. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2015 Aug 01. [cited 2018 Jul 13]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/citedownload/49966?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/citedownload/49966?format=enw">EndNote</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/citedownload/49966?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/citedownload/49966?format=txt">Medlars</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/citedownload/49966?format=ris">ProCite</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/citedownload/49966">RefWorks</a></li>
                            <li><a href="/web/20180713024956/https://www.guideline.gov/summaries/citedownload/49966?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="49966" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Treatment should be individualized based on patient and disease specific factors as determined by the treating clinician. The treatment recommendations included below are represented in the companion Management of Cutaneous Melanoma Stage IV treatment algorithm (see the "Availability of Companion Documents" field).</p>
<p>For American Joint Committee on Cancer melanoma staging, please refer to Appendix A in the original guideline document.</p>
<ol style="list-style-type: decimal;" start="1">
    <li>Patients with unresectable stage III and stage IV cutaneous melanoma should undergo BRAF biomarker testing by a College of Physicians and Surgeons of Alberta accredited laboratory to determine whether they are candidates for a BRAF inhibitor.
    <ul style="list-style-type: disc;">
        <li>Molecular validation should be performed using parallel testing with early access program testing kits; a reasonable number of duplicate test cases (i.e., 40 samples) should be performed. </li>
    </ul>
    </li>
    <li>First-line systemic therapy
    <ul style="list-style-type: disc;">
        <li>BRAF-positive patients
        <ul style="list-style-type: disc;">
            <li>Clinical trials </li>
            <li>Systemic targeted therapies for patients with high volume, symptomatic disease, or who are poor candidates to receive immunotherapy with ipilimumab. Examples of therapies include the following:
            <ul style="list-style-type: disc;">
                <li>Vemurafenib (960 mg orally, twice per day) + cobimetinib (60 mg orally, once daily for 21 days, followed by 7 days off) </li>
                <li>Dabrafenib (150 mg orally, twice per day) + trametinib (2 mg orally, once daily) </li>
            </ul>
            </li>
            <li>Anti-PD-1 (programmed cell death 1) antibody for patients with low volume, asymptomatic disease
            <ul style="list-style-type: disc;">
                <li>Pembrolizumab (2 mg/kg intravenous, every 3 weeks) <em>Note: This drug is not currently funded by the Alberta Health Services Drug Benefit Program</em> </li>
            </ul>
            </li>
            <li>Ipilimumab (3 mg/kg intravenous, every 3 weeks for 4 doses) for patients with low volume, asymptomatic disease </li>
        </ul>
        </li>
        <li>BRAF-negative patients
        <ul style="list-style-type: disc;">
            <li>Clinical trials </li>
            <li>Anti-PD-1 antibody
            <ul style="list-style-type: disc;">
                <li>Pembrolizumab (2 mg/kg intravenous, every 3 weeks) <em>Note: This drug is not currently funded by the Alberta Health Services Drug Benefit Program</em> </li>
            </ul>
            </li>
            <li>Ipilimumab (3 mg/kg intravenous, every 3 weeks for 4 doses) </li>
            <li>Consider targeted therapy for a defined subtype of melanoma mutational status (e.g., for c-kit positive tumors, consider c-kit inhibitors - <em>Note: These drugs are not currently funded by the Alberta Health Services Drug Benefit Program</em>) </li>
        </ul>
        </li>
    </ul>
    </li>
    <li>Second-line systemic therapy:
    <ul style="list-style-type: disc;">
        <li>Patients who are intolerant or who have progressed after first-line therapy may be considered for:
        <ul style="list-style-type: disc;">
            <li>Clinical trials </li>
            <li>If targeted therapy or anti-PD-1 antibody used as first-line consider ipilimumab </li>
            <li>If patient BRAF-positive and has not received or has not developed resistance to BRAF/mitogen-activated protein kinase (MEK) inhibition consider targeted therapy. </li>
            <li>If ipilimumab used as first-line consider targeted therapy, anti-PD-1 antibody or re-induction with ipilimumab (if patient had a response by modified World Health Organization [WHO] or immune-related response criteria [irRC] maintained for a period of 6 months or longer) </li>
        </ul>
        </li>
    </ul>
    </li>
</ol></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>An algorithm titled "Algorithm for the Management of Cutaneous Melanoma Stage IV" can be found in the "Availability of Companion Documents" field.</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Unresectable stage III or metastatic cutaneous melanoma</p>
<p class="Note"><strong>Note</strong>: The guideline does not include recommendations for the management of cutaneous in-transit melanoma, uveal, mucosal, or acral melanomas.</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Evaluation</p>
                    <p>Management</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Dermatology</p>
                    <p>Oncology</p>
                    <p>Pathology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To provide evidence-based recommendations on the medical management of unresectable stage III and metastatic melanoma</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Adults over the age of 18 years with unresectable stage III and stage IV cutaneous melanoma, without involvement of the central nervous system (CNS)</p>
<p class="Note"><strong>Note</strong>: Different management strategies may apply to pediatric patients. For patients with CNS metastases, the priority of treatment should typically focus on the CNS disease.</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;" start="1">
    <li>BRAF biomarker testing to determine if patients are candidates for a BRAF inhibitor </li>
    <li>Molecular validation using parallel testing with early access program testing kits </li>
    <li>First-line systemic therapy
    <ul style="list-style-type: disc;">
        <li>BRAF-positive patients: clinical trials, vemurafenib + cobimetinib, dabrafenib + trametinib, anti-PD-1 (programmed cell death 1) antibody (e.g., pembrolizumab), ipilimumab </li>
        <li>BRAF-negative patients: clinical trials, pembrolizumab, ipilimumab, targeted therapy for a defined subtype of melanoma mutational status (e.g., c-kit inhibitors) </li>
    </ul>
    </li>
    <li>Second-line systemic therapy
    <ul style="list-style-type: disc;">
        <li>Clinical trials </li>
        <li>Ipilimumab (if targeted therapy or anti-PD-1 was used in first-line) </li>
        <li>Targeted therapy (if there is no developed resistance to BRAF/mitogen-activated protein kinase [MEK] inhibition) </li>
        <li>Targeted therapy, anti-PD-1 or ipilimumab-re-induction (if ipilimumab was used in first-line) </li>
    </ul>
    </li>
</ol></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Survival rates (overall, progression-free)</li>
    <li>Tumour progression</li>
    <li>Response rates (objective, overall)</li>
    <li>Treatment-related adverse events</li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Hand-searches of Published Literature (Primary Sources)</p>
                    <p>Hand-searches of Published Literature (Secondary Sources)</p>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Research Questions</span></strong></p>
<p>Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (Patient or Population, Intervention, Comparisons, Outcomes).</p>
<p><strong><span style="text-decoration: underline;">Guideline Questions</span></strong></p>
<ul style="list-style-type: disc;">
    <li>What types of systemic therapy should be considered for patients with unresectable stage III or metastatic melanoma? </li>
    <li>Should patients be carefully selected; if so by what criteria? </li>
    <li>Which agents should be used as first-line therapy and at what dosing regimen? </li>
    <li>Which agents should be used as second- or third-line therapy and at what dosing regimen? </li>
</ul>
<p><strong><span style="text-decoration: underline;">Search Strategy</span></strong></p>
<p>Databases were searched for evidence on systemic therapy for unresectable stage III or metastatic cutaneous melanoma and citations were hand-searched to identify additional relevant studies. The initial search strategy and subsequent updates can be found in Appendix B in the original guideline document. Search terms include melanoma and specific types of systemic therapy. The 2015 update included randomized controlled trials, phase III and phase II studies with at least ten patients with advanced, unresectable melanoma. Additional key studies and abstracts were identified by working group members. The National Guidelines Clearinghouse (NGC) and individual guideline organizations were also searched for practice guidelines relevant to this topic.</p>
<p>The search was limited to humans and English from January 2013 to July 2015. 1613 citations were found.</p>
<p><strong>Date of Search</strong>: 07-14-2015</p>
<p><strong>Specific Topic Areas</strong>: Systemic therapy for advanced or metastatic melanoma</p>
<p><strong>Preliminary Update Search Strategy</strong>: PubMed and MEDLINE were searched for evidence on systemic therapy for unresectable stage III or metastatic cutaneous melanoma.</p>
<p><strong>Inclusion</strong>: Stage III or IV cutaneous melanoma, phase II or III studies, outcomes (overall survival, progression-free survival, tumour response)</p>
<p><strong>Exclusion</strong>: Active brain metastases, uveal, mucosal, or acral melanoma, retrospective studies, phase I studies</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>53 articles were included</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Expert Consensus</p>
                    <p>Expert Consensus (Committee)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Review of Published Meta-Analyses</p>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Cutaneous Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the GURU Handbook (see the "Availability of Companion Documents" field).</p>
<p><strong><span style="text-decoration: underline;">Evidence Tables</span></strong></p>
<p>Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic are assessed by the KM Specialist using portions of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (<a href="/web/20180713024956/https://www.guideline.gov/Home/Disclaimer?id=49966&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.agreetrust.org" title="AGREE Web site">http://www.agreetrust.org</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713024956im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>) and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Development and Revision History</span></strong></p>
<p>This guideline was reviewed and endorsed by the Alberta Provincial Cutaneous Tumour Team. Members of the Alberta Provincial Cutaneous Tumour Team include medical oncologists, surgeons, dermatologists, radiation oncologists, pathologists, and nurses. Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Cutaneous Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the GURU Handbook (see the "Availability of Companion Documents" field).</p>
<p><strong><span style="text-decoration: underline;">Formulating Recommendations</span></strong></p>
<p>The working group members formulate the guideline recommendations based on the interpretation of evidence synthesized by the KM Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the GURU handbook, the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.</p>
<p>The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the GURU does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>This guideline was reviewed and endorsed by the Alberta Provincial Cutaneous Tumour Team.</p>
<p><strong><span style="text-decoration: underline;">Guideline Review and Approval</span></strong></p>
<p>When the draft guideline document has been completed, revised, and reviewed by the Knowledge Management (KM) Specialist and the working group members, it is sent to all members of the Provincial Tumour Team for review and comment. This step ensures that those intended to use the guideline have the opportunity to review the document and identify potential difficulties for implementation before the guideline is finalized. Depending on the size of the document, and the number of people it is sent to for review, a deadline of one to two weeks will usually be given to submit any feedback. Ideally, this review will occur prior to the annual Provincial Tumour Team meeting, and a discussion of the proposed edits will take place at the meeting. The working group members will then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it is officially endorsed by the Provincial Tumour Team Lead and the Director of Provincial Clinical Teams.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of evidence supporting the recommendations is not specifically stated.</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Optimal selection of systemic agents for the management of unresectable stage III or metastatic cutaneous melanoma</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>The most common adverse events for trametinib in the METRIC study were rash, diarrhea, and peripheral edema; events were managed with dose interruption and dose reduction. </li>
    <li>Combination therapy of BRAF inhibitors and mitogen-activated protein kinase (MEK) inhibitors both had similar rates of adverse events; however, more dose modifications were documented in combination group. </li>
    <li>In a phase III study (KEYNOTE-006), the most common events observed in the pembrolizumab groups were fatigue, diarrhea, rash and pruritus. </li>
</ul></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>The recommendations contained in this guideline are a consensus of the Alberta Provincial Cutaneous Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Present the guideline at the local and provincial tumour team meetings and weekly rounds. </li>
    <li>Post the guideline on the Alberta Health Services Web site. </li>
    <li>Send an electronic notification of the guideline to all members of CancerControl Alberta. </li>
</ul></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Clinical Algorithm</p>
                    <p>Resources</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Alberta Provincial Cutaneous Tumour Team. Systemic therapy for unresectable stage III or metastatic cutaneous melanoma. Edmonton (AB): CancerControl Alberta; 2015 Aug. 14 p.&nbsp;(Clinical practice guideline; no. CU-012).&nbsp; [43 references]</td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2015 Aug</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>CancerControl Alberta - State/Local Government Agency [Non-U.S.]</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>CancerControl Alberta</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Alberta Provincial Cutaneous Tumour Team</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p>Members of the Alberta Provincial Cutaneous Tumour Team include medical oncologists, surgeons, dermatologists, radiation oncologists, pathologists, and nurses.</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Participation of members of the Alberta Provincial Cutaneous Tumour Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. There was no direct industry involvement in the development or dissemination of this guideline. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Cutaneous Tumour Team are involved in research funded by industry or have other such potential conflicts of interest. However, the developers of this guideline are satisfied it was developed in an unbiased manner.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Alberta Provincial Cutaneous Tumour Team. Systemic therapy for unresectable stage III or metastatic cutaneous melanoma. Edmonton (Alberta): CancerControl Alberta; 2013 Feb. 13 p. (Clinical practice guideline; no. CU-012). [59 references]</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available from the <a href="/web/20180713024956/https://www.guideline.gov/Home/Disclaimer?id=49966&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.albertahealthservices.ca%2fassets%2finfo%2fhp%2fcancer%2fif-hp-cancer-guide-cu012-systemic-therapy.pdf" title="Alberta Health Services Web site">Alberta Health Services Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713024956im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Guideline utilization resource unit handbook. Version 2. Edmonton (AB): CancerControl Alberta; 2013 Jan. 5 p. </li>
    <li>Algorithm for the management of cutaneous melanoma stage IV. Edmonton (AB): CancerControl Alberta; 2015 Aug. 1 p. Available from the <a href="/web/20180713024956/https://www.guideline.gov/Home/Disclaimer?id=49966&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.albertahealthservices.ca%2fassets%2finfo%2fhp%2fcancer%2fif-hp-cancer-guide-algorithm-stage-iv.pdf" title="Alberta Health Services Web site">Alberta Health Services Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713024956im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul>
<p>In addition, the American Joint Committee on Cancer (AJCC) (7th Edition) anatomic stage groupings and the tumour, node, metastases (TNM) staging categories for cutaneous melanoma are available in Appendix A of the <a href="/web/20180713024956/https://www.guideline.gov/Home/Disclaimer?id=49966&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.albertahealthservices.ca%2fassets%2finfo%2fhp%2fcancer%2fif-hp-cancer-guide-cu012-systemic-therapy.pdf" title="Alberta Health Services Web site">original guideline document</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713024956im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on December 10, 2012. The information was verified by the guideline developer on January 23, 2013. This summary was updated by ECRI Institute on April 28, 2014. The updated information was verified by the guideline developer on June 6, 2014. This summary was updated again by ECRI Institute on March 14, 2016. The updated information was verified by the guideline developer on April 4, 2016.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180713024956/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180713024956/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180713024956/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713024956/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713024956/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713024956/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713024956/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713024956/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180713024956/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180713024956/https://www.guideline.gov/disclaimer?id=49966&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180713024956/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180713024956/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180713024956/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180713024956/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180713024956/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180713024956/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180713024956/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180713024956/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180713024956/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180713024956/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180713024956/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180713024956/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180713024956/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180713024956/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180713024956im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180713024956/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180713024956/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180713024956js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180713024956js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 02:49:56 Jul 13, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 16:46:58 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 133.316 (3)
  esindex: 0.01
  captures_list: 158.452
  CDXLines.iter: 15.998 (3)
  PetaboxLoader3.datanode: 121.302 (4)
  exclusion.robots: 0.175
  exclusion.robots.policy: 0.164
  RedisCDXSource: 5.572
  PetaboxLoader3.resolve: 248.965
  load_resource: 275.991
-->